Plotkin is sometimes called the “godfather of vaccines.” His contributions to vaccinology are so substantial, they literally ...

Federal investment in RNA vaccine research has supported nearly three decades of scientific work spanning infectious diseases, cancer, and vaccine development, but recent and proposed funding cuts ...

While current flu shots need to be updated each season, scientists are finding new ways to make vaccine that could last much longer and cover more strains.

The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine ...

Platform-enabled vaccine design unlocks safer, more effective solutions with outer-membrane vesicles (OMVs) emerging as next-generation technology.

A challenging public health policy landscape under health secretary Robert F. Kennedy has vaccine makers rethinking developing for the U.S. market.

Despite its long history, vaccination remains an effective means of reducing infectious disease susceptibility and transmission. As bacterial, viral, fungal, and protozoan pathogens continue to ...

RNA-based immunizing agents have enriched the repertoire of technologies used for vaccine development. An analysis of the active clinical trials in early Phase I and Phase I during the year of 2023 ...

A recent study shows how scientists try to assess vaccines honestly, then improve them incrementally — offering a solid contrast to conspiracy theories.

Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...

As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the ...